# A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.

> **NCT00560274** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 190 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** Pegasys
- **DRUG:** Ribavirin
- **DRUG:** epoetin beta [NeoRecormon]

## Key facts

- **NCT ID:** NCT00560274
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2016-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00560274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00560274, "A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00560274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*